Hemorrhage, Surgical

0
Pipeline Programs
1
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

CytoSorbents
CytoSorbentsPRINCETON, NJ
3 programs
CytoSorbN/A1 trial
DrugSorb-ATR systemN/A1 trial
Sham comparatorN/A1 trial
Active Trials
NCT05077124Recruiting1,000Est. Sep 2025
NCT04976530Completed140Est. Aug 2023
NCT05093504Terminated9Est. Jan 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CytoSorbentsSham comparator
CytoSorbentsCytoSorb
CytoSorbentsDrugSorb-ATR system

Clinical Trials (3)

Total enrollment: 1,149 patients across 3 trials

Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)

Start: Dec 2021Est. completion: Jan 20249 patients
N/ATerminated

Safe and Timely Antithrombotic Removal (STAR) Registry

Start: Sep 2021Est. completion: Sep 20251,000 patients
N/ARecruiting
NCT04976530CytoSorbentsDrugSorb-ATR system

Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)

Start: Aug 2021Est. completion: Aug 2023140 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 1,149 patients
1 companies competing in this space